The FDA is experiencing a significant loss of experienced personnel amid low morale and heightened political interference. Following a reduction of 19% of its workforce coinciding with the appointment of Commissioner Marty Makary, staff cite impacted regulatory operations across drug, device, biologics, and food centers. Concerns include the sidelining of career expertise and a near six-month government hiring freeze, raising questions about the agency's capacity to maintain its regulatory rigor and timelines.